Neoadjuvant Treatment with Paclitaxel and Epirubicin in Invasive??Breast Cancer-Reference-Cited by-同舟云学术

Neoadjuvant Treatment with Paclitaxel and Epirubicin in Invasive??Breast Cancer

Published:2006 Issue:12 Volume:26 Page:691-701
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clinical Drug Investigation

Author:

Sarid David,Ron Ilan G,Sperber Fani,Stadler Yona,Kahan Perry,Kovner Felix,Ben-Yosef Rami,Marmor Sylvia,Grinberg Yulia,Maimon Natalie,Weinstein Juliana,Yaal-Hahoshen Neora

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Reference31 articles.

1. LOCALLY ADVANCED NONINFLAMMATORY BREAST CANCER

2. Primary Systemic Therapy of Breast Cancer

3. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

4. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

5. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer;OncoTargets and Therapy;2023-04

2. Fever and breast cancer: A critical review of the literature and possible underlying mechanisms;Breast Disease;2021-07-15

3. Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress;Antioxidants & Redox Signaling;2011-11

4. A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer;Community Oncology;2011-05

5. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy;Oncology;2011